Anna Pfenniger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Pfenniger has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Rishi Arora
Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
7 shared publications - Bradley P. Knight
Feinberg School of Medicine, Division of Cardiology Northwestern University Chicago Illinois USA
6 shared publications - Rod Passman
Division of Cardiology, Feinberg School of Medicine, Northwestern University , 676 N St Claire, Suite 600, Chicago, IL 60611
4 shared publications - Shin Yoo
Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
4 shared publications - David A. Johnson
Feinberg Cardiovascular and Renal Research Institute Northwestern University Feinberg School of Medicine Chicago IL USA
3 shared publications Rishi Arora
University of Chicago
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 331 (4) , H1212-H1213
When ventricular load outruns atrial reserve
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 331 (4) , H1212-H1213
Open AccessWhen ventricular load outruns atrial reserve
- 30 September 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
Rare Cardiac Genetic Variation Is Associated With Postoperative Atrial Fibrillation
BACKGROUND: New-onset postoperative atrial fibrillation (POAF) is a common surgical complication, yet the contribution of rare genetic variants to POAF is poorly characterized. METHODS: We conducted a cohort study including 49 913 adults who underwent surgery without a preoperative diagnosis of atrial fibrillation (AF). All participants had whole-genome sequencing linked to electronic health record data. Pathogenic or likely pathogenic (LP) variants were identified in 141 cardiac genes associated with early-onset AF. The primary outcome was POAF, defined as a new diagnosis of AF within 30 days of surgery; the secondary outcome was freedom from AF over 5 years. Multivariable regression and propensity-score matching were used to evaluate the associations between pathogenic/LP variants and POAF. RESULTS: Among 49 913 participants, 2298 underwent cardiac surgery and 47 615 underwent noncardiac surgery. The prevalence of pathogenic/LP variants was 6.0% in the cardiac surgery group (138/2298) and 4.1% in the noncardiac surgery group (1947/47 615). Overall, carriers of ≥1 pathogenic/LP variant had higher odds of POAF than noncarriers (6.6% versus 4.0%; odds ratio [OR], 1.8 [95% CI, 1.4–2.1]). In cardiac surgery, 36.0% of pathogenic/LP carriers (78/216) developed POAF versus 23.4% of noncarriers (492/2082; OR, 2.3 [95% CI, 1.4–3.2]), and in noncardiac surgery, POAF occurred in 3.8% of carriers (74/1947) versus 2.5% of noncarriers (1465/45 668; OR, 1.5 [95% CI, 1.2–1.9]). Pathogenic/LP variants in cardiomyopathy-only genes (n=589; OR, 1.8 [95% CI, 1.3–2.6]) or in genes associated with both cardiomyopathy and arrhythmia (n=1059; OR, 1.8 [95% CI, 1.4–2.3]) were significantly associated with POAF, whereas variants in arrhythmia-only genes (n=454; OR, 1.3 [95% CI, 0.8–2.1]) were not. Five-year freedom from AF was lower among pathogenic/LP variant carriers in both cardiac surgery (53% versus 64%; P =0.010) and noncardiac surgery (92% versus 94%; P =0.002). CONCLUSIONS: Rare pathogenic/LP variants in cardiomyopathy genes were associated with risk of POAF and reduced AF-free survival over long-term follow-up across cardiac and noncardiac surgery.
- 30 September 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
Rare Cardiac Genetic Variation Is Associated With Postoperative Atrial Fibrillation
BACKGROUND: New-onset postoperative atrial fibrillation (POAF) is a common surgical complication, yet the contribution of rare genetic variants to POAF is poorly characterized. METHODS: We conducted a cohort study including 49 913 adults who underwent surgery without a preoperative diagnosis of atrial fibrillation (AF). All participants had whole-genome sequencing linked to electronic health record data. Pathogenic or likely pathogenic (LP) variants were identified in 141 cardiac genes associated with early-onset AF. The primary outcome was POAF, defined as a new diagnosis of AF within 30 days of surgery; the secondary outcome was freedom from AF over 5 years. Multivariable regression and propensity-score matching were used to evaluate the associations between pathogenic/LP variants and POAF. RESULTS: Among 49 913 participants, 2298 underwent cardiac surgery and 47 615 underwent noncardiac surgery. The prevalence of pathogenic/LP variants was 6.0% in the cardiac surgery group (138/2298) and 4.1% in the noncardiac surgery group (1947/47 615). Overall, carriers of ≥1 pathogenic/LP variant had higher odds of POAF than noncarriers (6.6% versus 4.0%; odds ratio [OR], 1.8 [95% CI, 1.4–2.1]). In cardiac surgery, 36.0% of pathogenic/LP carriers (78/216) developed POAF versus 23.4% of noncarriers (492/2082; OR, 2.3 [95% CI, 1.4–3.2]), and in noncardiac surgery, POAF occurred in 3.8% of carriers (74/1947) versus 2.5% of noncarriers (1465/45 668; OR, 1.5 [95% CI, 1.2–1.9]). Pathogenic/LP variants in cardiomyopathy-only genes (n=589; OR, 1.8 [95% CI, 1.3–2.6]) or in genes associated with both cardiomyopathy and arrhythmia (n=1059; OR, 1.8 [95% CI, 1.4–2.3]) were significantly associated with POAF, whereas variants in arrhythmia-only genes (n=454; OR, 1.3 [95% CI, 0.8–2.1]) were not. Five-year freedom from AF was lower among pathogenic/LP variant carriers in both cardiac surgery (53% versus 64%; P =0.010) and noncardiac surgery (92% versus 94%; P =0.002). CONCLUSIONS: Rare pathogenic/LP variants in cardiomyopathy genes were associated with risk of POAF and reduced AF-free survival over long-term follow-up across cardiac and noncardiac surgery.
- 1 November 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (5) , C1439-C1450
Autonomic dysregulation and atrial arrhythmias
The autonomic nervous system (ANS) and its dysregulation are recognized as important mechanisms underlying atrial arrhythmias, such as atrial fibrillation (AF). In this review, we describe the anatomy of the cardiac nervous system, sympathetic and parasympathetic effects on atrial electrophysiology, and how dysregulation of those may predispose to AF initiation and promote its maintenance. We then discuss how the ANS itself undergoes functional and structural remodeling in the setting of atrial arrhythmias, and what are the current neuromodulation approaches for AF prevention and treatment. These strategies include destruction of cardiac ANS structures or modification of autonomic signaling using nerve stimulation, pharmacological or gene therapy. Autonomic mechanisms of AF have been a focus of basic and translational research for many years, and now with the development of new diagnostic tools and therapeutic methods, ANS-targeted approaches have a potential to become an important part of AF treatment.
- 1 November 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (5) , C1439-C1450
Autonomic dysregulation and atrial arrhythmias
The autonomic nervous system (ANS) and its dysregulation are recognized as important mechanisms underlying atrial arrhythmias, such as atrial fibrillation (AF). In this review, we describe the anatomy of the cardiac nervous system, sympathetic and parasympathetic effects on atrial electrophysiology, and how dysregulation of those may predispose to AF initiation and promote its maintenance. We then discuss how the ANS itself undergoes functional and structural remodeling in the setting of atrial arrhythmias, and what are the current neuromodulation approaches for AF prevention and treatment. These strategies include destruction of cardiac ANS structures or modification of autonomic signaling using nerve stimulation, pharmacological or gene therapy. Autonomic mechanisms of AF have been a focus of basic and translational research for many years, and now with the development of new diagnostic tools and therapeutic methods, ANS-targeted approaches have a potential to become an important part of AF treatment.
- 15 October 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (12) , 1819-1821
Heart Failure and Atrial Fibrillation: Diagnose One, Anticipate the Other
- 15 October 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (12) , 1819-1821
Heart Failure and Atrial Fibrillation: Diagnose One, Anticipate the Other
- Top Cited PapersOpen Access
- 29 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (35) , eadw3044
High-resolution liquid metal–based stretchable electronics enabled by colloidal self-assembly and microtransfer printing
Liquid metal–based stretchable electronics offer high electrical performance and seamless integration with deformable systems but face challenges in achieving scalable, high-resolution patterning. In this work, we present a method for micropatterning liquid metal particle (LMP) films with feature sizes as small as 5 micrometers by integrating electrostatically enabled colloidal self-assembly and microtransfer printing. The resulting cold-welded LMP micropatterns exhibit exceptional electromechanical properties, high conductivity (2.4 × 10 6 siemens per meter), stretchability (more than 1200%), and strain- and pressure-insensitive resistance, owing to their multiscale and dynamic morphologies. Demonstrations in highly stretchable strain sensors and cardiac mapping devices highlight the capabilities of this method for creating high-performance, highly stretchable electronic systems. Notably, balloon catheter–integrated LMP microelectrode arrays show low impedance under extreme deformations and enable high-resolution endocardial electrogram mapping inside the human heart. This method expands the potential of liquid metal–based stretchable electronics for a wide range of applications, including implantable biomedical devices and soft robotics.
- 29 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (35) , eadw3044
Top Cited PapersOpen AccessHigh-resolution liquid metal–based stretchable electronics enabled by colloidal self-assembly and microtransfer printing
Liquid metal–based stretchable electronics offer high electrical performance and seamless integration with deformable systems but face challenges in achieving scalable, high-resolution patterning. In this work, we present a method for micropatterning liquid metal particle (LMP) films with feature sizes as small as 5 micrometers by integrating electrostatically enabled colloidal self-assembly and microtransfer printing. The resulting cold-welded LMP micropatterns exhibit exceptional electromechanical properties, high conductivity (2.4 × 10 6 siemens per meter), stretchability (more than 1200%), and strain- and pressure-insensitive resistance, owing to their multiscale and dynamic morphologies. Demonstrations in highly stretchable strain sensors and cardiac mapping devices highlight the capabilities of this method for creating high-performance, highly stretchable electronic systems. Notably, balloon catheter–integrated LMP microelectrode arrays show low impedance under extreme deformations and enable high-resolution endocardial electrogram mapping inside the human heart. This method expands the potential of liquid metal–based stretchable electronics for a wide range of applications, including implantable biomedical devices and soft robotics.
- Open Access
- 5 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (5) , e9011
Use of Atrial Fibrillation Electrograms and T1/T2 Magnetic Resonance Imaging to Define the Progressive Nature of Molecular and Structural Remodeling: A New Paradigm Underlying the Emergence of Persistent Atrial Fibrillation
Background: The temporal progression states of the molecular and structural substrate in atrial fibrillation (AF) are not well understood. We hypothesized that these can be detected by AF electrograms and magnetic resonance imaging parametric mapping. Methods and Results: AF was induced in 43 dogs (25–35 kg, ≥1 year) by rapid atrial pacing (RAP) (3–33 weeks, 600 beats/min), and 4 controls were used. We performed high‐resolution epicardial mapping (UnEmap, 6 atrial regions, both atria, 130 electrodes, distance 2.5 mm) and analyzed electrogram cycle length, dominant frequency, organization index, and peak‐to‐peak bipolar voltage. Implantable telemetry recordings were used to quantify parasympathetic nerve activity over RAP time. Magnetic resonance imaging native T1, postcontrast T1, T2 mapping, and extracellular volume fraction were assessed (1.5T, Siemens) at baseline and AF. In explanted atrial tissue, DNA oxidative damage (8‐hydroxy‐2′‐deoxyguanosine staining) and percentage of fibrofatty tissue were quantified. Cycle length and organization index decreased ( R =0.5, P R =0.5, P R =0.3, P n.s.) until 80 days of RAP but not thereafter. In contrast, voltage continued to decrease throughout the duration of RAP ( R =0.6, P R =0.5, P R =0.6, P R =0.5, P <0.05 for both). Conclusions: A combination of AF electrogram characteristics and T1/T2 magnetic resonance imaging can detect early‐stage AF remodeling (autonomic remodeling, oxidative stress) and advanced AF remodeling due to oxidative stress and fibrosis.
- 5 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (5) , e9011
Open AccessUse of Atrial Fibrillation Electrograms and T1/T2 Magnetic Resonance Imaging to Define the Progressive Nature of Molecular and Structural Remodeling: A New Paradigm Underlying the Emergence of Persistent Atrial Fibrillation
Background: The temporal progression states of the molecular and structural substrate in atrial fibrillation (AF) are not well understood. We hypothesized that these can be detected by AF electrograms and magnetic resonance imaging parametric mapping. Methods and Results: AF was induced in 43 dogs (25–35 kg, ≥1 year) by rapid atrial pacing (RAP) (3–33 weeks, 600 beats/min), and 4 controls were used. We performed high‐resolution epicardial mapping (UnEmap, 6 atrial regions, both atria, 130 electrodes, distance 2.5 mm) and analyzed electrogram cycle length, dominant frequency, organization index, and peak‐to‐peak bipolar voltage. Implantable telemetry recordings were used to quantify parasympathetic nerve activity over RAP time. Magnetic resonance imaging native T1, postcontrast T1, T2 mapping, and extracellular volume fraction were assessed (1.5T, Siemens) at baseline and AF. In explanted atrial tissue, DNA oxidative damage (8‐hydroxy‐2′‐deoxyguanosine staining) and percentage of fibrofatty tissue were quantified. Cycle length and organization index decreased ( R =0.5, P R =0.5, P R =0.3, P n.s.) until 80 days of RAP but not thereafter. In contrast, voltage continued to decrease throughout the duration of RAP ( R =0.6, P R =0.5, P R =0.6, P R =0.5, P <0.05 for both). Conclusions: A combination of AF electrogram characteristics and T1/T2 magnetic resonance imaging can detect early‐stage AF remodeling (autonomic remodeling, oxidative stress) and advanced AF remodeling due to oxidative stress and fibrosis.
- Top Cited Papers
- 26 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 376 (6596) , 1006-1012
A transient, closed-loop network of wireless, body-integrated devices for autonomous electrotherapy
Temporary postoperative cardiac pacing requires devices with percutaneous leads and external wired power and control systems. This hardware introduces risks for infection, limitations on patient mobility, and requirements for surgical extraction procedures. Bioresorbable pacemakers mitigate some of these disadvantages, but they demand pairing with external, wired systems and secondary mechanisms for control. We present a transient closed-loop system that combines a time-synchronized, wireless network of skin-integrated devices with an advanced bioresorbable pacemaker to control cardiac rhythms, track cardiopulmonary status, provide multihaptic feedback, and enable transient operation with minimal patient burden. The result provides a range of autonomous, rate-adaptive cardiac pacing capabilities, as demonstrated in rat, canine, and human heart studies. This work establishes an engineering framework for closed-loop temporary electrotherapy using wirelessly linked, body-integrated bioelectronic devices.
- 26 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 376 (6596) , 1006-1012
Top Cited PapersA transient, closed-loop network of wireless, body-integrated devices for autonomous electrotherapy
Temporary postoperative cardiac pacing requires devices with percutaneous leads and external wired power and control systems. This hardware introduces risks for infection, limitations on patient mobility, and requirements for surgical extraction procedures. Bioresorbable pacemakers mitigate some of these disadvantages, but they demand pairing with external, wired systems and secondary mechanisms for control. We present a transient closed-loop system that combines a time-synchronized, wireless network of skin-integrated devices with an advanced bioresorbable pacemaker to control cardiac rhythms, track cardiopulmonary status, provide multihaptic feedback, and enable transient operation with minimal patient burden. The result provides a range of autonomous, rate-adaptive cardiac pacing capabilities, as demonstrated in rat, canine, and human heart studies. This work establishes an engineering framework for closed-loop temporary electrotherapy using wirelessly linked, body-integrated bioelectronic devices.
- 23 September 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (12) , 3117-3124
Use of a novel 4D intracardiac echocardiography catheter to guide interventional electrophysiology procedures
Introduction: Standard two‐dimensional (2D), phased‐array intracardiac echocardiography (ICE) is routinely used to guide interventional electrophysiology (EP) procedures. A novel four‐dimensional (4D) ICE catheter (VeriSight Pro, Philips) can obtain 2D and three‐dimensional (3D) volumetric images and cine‐videos in real‐time (4D). The purpose of this study was to determine the early feasibility and safety of this 4D ICE catheter during EP procedures.Methods: The 4D ICE catheter was placed from the femoral vein in ten patients into various cardiac chambers to guide EP procedures requiring transseptal catheterization, including ablation for atrial fibrillation and left atrial appendage closure. 2D‐ and 3D‐ICE images were acquired in real‐time by the electrophysiologist. A dedicated imaging expert performed digital steering to optimize and postprocess 4D images.Results: Eight patients underwent pulmonary vein isolation (cryoballoon in seven patients, pulsed field ablation in one, additional radiofrequency left atrial ablation in one). Two patients underwent left atrial appendage closure. High quality images of cardiac structures, transseptal catheterization equipment, guide sheaths, ablation tools, and closure devices were acquired with the ICE catheter tip positioned in the right atrium, left atrium, pulmonary vein, coronary sinus, right ventricle, and pulmonary artery. There were no complications.Conclusion: This is the first experience of a novel deflectable 4D ICE catheter used to guide EP procedures. 4D ICE imaging is safe and allows for acquisition of high‐quality 2D and 3D images in real‐time. Further use of 4D ICE will be needed to determine its added value for each EP procedure type.
- 23 September 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (12) , 3117-3124
Use of a novel 4D intracardiac echocardiography catheter to guide interventional electrophysiology procedures
Introduction: Standard two‐dimensional (2D), phased‐array intracardiac echocardiography (ICE) is routinely used to guide interventional electrophysiology (EP) procedures. A novel four‐dimensional (4D) ICE catheter (VeriSight Pro, Philips) can obtain 2D and three‐dimensional (3D) volumetric images and cine‐videos in real‐time (4D). The purpose of this study was to determine the early feasibility and safety of this 4D ICE catheter during EP procedures.Methods: The 4D ICE catheter was placed from the femoral vein in ten patients into various cardiac chambers to guide EP procedures requiring transseptal catheterization, including ablation for atrial fibrillation and left atrial appendage closure. 2D‐ and 3D‐ICE images were acquired in real‐time by the electrophysiologist. A dedicated imaging expert performed digital steering to optimize and postprocess 4D images.Results: Eight patients underwent pulmonary vein isolation (cryoballoon in seven patients, pulsed field ablation in one, additional radiofrequency left atrial ablation in one). Two patients underwent left atrial appendage closure. High quality images of cardiac structures, transseptal catheterization equipment, guide sheaths, ablation tools, and closure devices were acquired with the ICE catheter tip positioned in the right atrium, left atrium, pulmonary vein, coronary sinus, right ventricle, and pulmonary artery. There were no complications.Conclusion: This is the first experience of a novel deflectable 4D ICE catheter used to guide EP procedures. 4D ICE imaging is safe and allows for acquisition of high‐quality 2D and 3D images in real‐time. Further use of 4D ICE will be needed to determine its added value for each EP procedure type.
- 6 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (10) , 2854-2864
Recent advances in gene therapy for atrial fibrillation
Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke. Unfortunately, current treatments for AF are suboptimal as they are not targeting the molecular mechanisms underlying AF. In this regard, gene therapy is emerging as a promising approach for mechanism‐based treatment of AF. In this review, we summarize recent advances and challenges in gene therapy for this important cardiovascular disease.
- 6 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (10) , 2854-2864
Recent advances in gene therapy for atrial fibrillation
Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke. Unfortunately, current treatments for AF are suboptimal as they are not targeting the molecular mechanisms underlying AF. In this regard, gene therapy is emerging as a promising approach for mechanism‐based treatment of AF. In this review, we summarize recent advances and challenges in gene therapy for this important cardiovascular disease.
- 5 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (8) , 2097-2104
Impact of pre‐ablation weight loss on the success of catheter ablation for atrial fibrillation
Introduction: Obesity is an established risk factor for recurrent atrial fibrillation (AF) after ablation. The impact of pre‐procedure weight changes on freedom from AF (FFAF) after ablation in obese and nonobese patients is unknown.Methods: A single‐center retrospective cohort study of patients undergoing pulmonary vein isolation was performed. Before ablation, all candidates were encouraged to adopt healthy lifestyle habits according to American Heart Association guidelines, including weight loss, by their physician. The primary endpoint was FFAF through 1‐year after completion of the 3‐month blanking period.Results: Of the 601 patients (68% male; average age 62.1 ± 10.3 years) included in analysis, 234 patients (38.9%) were obese (body mass index ≥ 30) and 315 (52.4%) had paroxysmal AF. FFAF was observed in 420 patients (69.9%) at 15 months. Percent change in weight that occurred during the year before ablation independently predicted FFAF through 15‐months in all patients (adjusted odds ratio = 1.17, 95% confidence interval: 1.11–1.23). Subgroup analyses based on paroxysmal vs persistent AF, presence of obesity, and history of prior ablation were performed. Percent change in weight over the year before ablation was independently associated with FFAF in all subgroups except nonobese patients with persistent AF.Conclusion: Pre‐ablation weight loss was associated with FFAF in both obese and nonobese patients. Further studies are needed to define the optimal approach to weight loss before AF ablation.
- 5 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (8) , 2097-2104
Impact of pre‐ablation weight loss on the success of catheter ablation for atrial fibrillation
Introduction: Obesity is an established risk factor for recurrent atrial fibrillation (AF) after ablation. The impact of pre‐procedure weight changes on freedom from AF (FFAF) after ablation in obese and nonobese patients is unknown.Methods: A single‐center retrospective cohort study of patients undergoing pulmonary vein isolation was performed. Before ablation, all candidates were encouraged to adopt healthy lifestyle habits according to American Heart Association guidelines, including weight loss, by their physician. The primary endpoint was FFAF through 1‐year after completion of the 3‐month blanking period.Results: Of the 601 patients (68% male; average age 62.1 ± 10.3 years) included in analysis, 234 patients (38.9%) were obese (body mass index ≥ 30) and 315 (52.4%) had paroxysmal AF. FFAF was observed in 420 patients (69.9%) at 15 months. Percent change in weight that occurred during the year before ablation independently predicted FFAF through 15‐months in all patients (adjusted odds ratio = 1.17, 95% confidence interval: 1.11–1.23). Subgroup analyses based on paroxysmal vs persistent AF, presence of obesity, and history of prior ablation were performed. Percent change in weight over the year before ablation was independently associated with FFAF in all subgroups except nonobese patients with persistent AF.Conclusion: Pre‐ablation weight loss was associated with FFAF in both obese and nonobese patients. Further studies are needed to define the optimal approach to weight loss before AF ablation.